FDA Pushback on Accelerated Gene Therapy Approvals
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
FDA Pushback on Accelerated Gene Therapy Approvals
-
Narrated by:
-
By:
About this listen
In this episode, Edye Edens dives into the FDA’s evolving scrutiny of accelerated approvals in gene therapy and rare diseases. Using the example of Sarepta’s muscular dystrophy treatment, she explains how postmarket safety issues and incomplete confirmatory trials can put previously celebrated approvals under renewed FDA evaluation.
Edye breaks down three common pitfalls sponsors face:
- Lagging confirmatory trials
- Outdated safety monitoring plans
- Poor communication across teams and with FDA
She offers practical guidance to avoid regulatory setbacks:
- Build flexible governance frameworks
- Stay proactive with FDA engagement
- Plan for legal and regulatory risks in confirmatory trials
- Prepare for public, regulatory, and payer scrutiny post-approval
Accelerated approval is a major milestone—but it’s not the end. It's the beginning of the next regulatory chapter. Tune in to learn how to manage post-approval responsibilities and secure long-term success for your therapy.
Like, comment, or reach out to learn more.
Support the show
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.